# A single, interpretable vocal biomarker for enriching antipsychotic clinical trials

**URL:** <https://schizophreniasupport.discourse.group/t/a-single-interpretable-vocal-biomarker-for-enriching-antipsychotic-clinical-trials/1407>\
**Category:** News on schizophrenia and mental health matters\
**Created:** [January 8, 2026, 1:20pm UTC](https://schizophreniasupport.discourse.group/t/a-single-interpretable-vocal-biomarker-for-enriching-antipsychotic-clinical-trials/1407 "2026-01-08T13:20:43Z")\
**Posts on this page:** 2\
**Page:** 1

<div class="post-metadata">

**Author:** ![everhopeful](https://yyz2.discourse-cdn.com/flex012/user_avatar/schizophreniasupport.discourse.group/everhopeful/32/605_2.png) [@everhopeful](https://schizophreniasupport.discourse.group/u/everhopeful)\
**Post date:** [January 8, 2026, 1:20pm UTC](https://schizophreniasupport.discourse.group/t/a-single-interpretable-vocal-biomarker-for-enriching-antipsychotic-clinical-trials/1407/1 "2026-01-08T13:20:43Z")

</div>

[https://www.biologicalpsychiatryjournal.com/article/S0006-3223(25)01676-2/abstract](https://www.biologicalpsychiatryjournal.com/article/S0006-3223(25)01676-2/abstract)

> **Speech latency** showed excellent internal consistency, good temporal stability, and minimal convergence with potential confounders. **Patients with (vs patients without) moderate-to-severe negative symptoms showed longer speech latencies**, with large effect sizes observed in every country (Cohen’s d=0.83 to 1.47).

---

<div class="post-metadata">

**Author:** ![SzSupportAdmin](https://yyz2.discourse-cdn.com/flex012/user_avatar/schizophreniasupport.discourse.group/szsupportadmin/32/334_2.png) [@SzSupportAdmin](https://schizophreniasupport.discourse.group/u/SzSupportAdmin)\
**Post date:** [January 21, 2026, 10:48pm UTC](https://schizophreniasupport.discourse.group/t/a-single-interpretable-vocal-biomarker-for-enriching-antipsychotic-clinical-trials/1407/2 "2026-01-21T22:48:55Z")

</div>